Uncategorized Archives - Page 2 of 5 - HealthCare Royalty

August 3, 2023

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

May 15, 2023

uniQure Announces Sale of Royalty Interest in HEMGENIX ^® for Up To $400 Million

January 9, 2023

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

December 21, 2022

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

June 30, 2022

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

June 16, 2022

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

June 24, 2021

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

March 31, 2021

Aptevo Therapeutics Announces Sale of Ruxience Royalty Payments to HCR

March 29, 2021

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

September 10, 2020

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US